Review
Copyright ©The Author(s) 2015.
World J Virology. Nov 12, 2015; 4(4): 343-355
Published online Nov 12, 2015. doi: 10.5501/wjv.v4.i4.343
Table 3 Treatment of chronic hepatitis E virus with ribavirin regimen
Ref.Type of studyPatient profileRibavirin regimenResultAdverse effects
Kamar et al[99]Prospective case series6 kidney transplant recipients, HEV RNA (+) for median of 36.5 mo600-800 mg/d for 3 mo adapted to GFR, HgbSVR in 4/6 patients; relapse in 2/6; AST, ALT normalized allAnemia led to blood transfusion and RBV dose reduction in 2/6 patients
Mallet et al[105]Case reportA kidney and pancreas transplanted man, a women with idiopathic CD4+ T lymphocytopenia12 mg/kg daily for 12 wkBoth cleared HEV after 4 wk of treatment and remained undetectable, LFT normalizedAnemia in 1st patient led to Ribavirin dose reduction to 200 mg/d
Pischke et al[96]Prospective case seriesOrgan transplant recipients 11 subjects600-1000 mg/d for 5 mo, dose reduction according to Hgb or anemia9/11 showed SVRAnemia, the mean Hgb decline was 3.4 g/dL (range 0-7.9 g/dL)
Neukam et al[106]Case report2 HIV (+) male with liver cirrhosis with severe immunosuppressionOral ribavirin 1200 mg/d (case 1) 1000 mg/d (case 2) for 24 wkLFT normalized-Liver stiffness improved HEV RNA was detected after the end of treatment in both patients-
Giordani et al[107]Case report60-year-old man with lymphocytic leukemia1000 mg/d in 2 doses (400 and 600 mg), for 3 moHEV cleared and sustained over 6 mo after therapyMild anemia (Hgb 10.5 mg/dL)
Kamar et al[100]Retrospective, multicentre case series37 kidney, 10 liver, 5 heart, 5 kidneys and pancreas, and 2 lung transplant recipients with chronic HEVMedian dose of 600 mg/d (range 29-1200), for a median of 3 mo (range 1-18 mo)At the end of the therapy, 95% cleared HEV, 18% recurred after cessation of therapy is stopped, 78% showed SVRAnemia required dose reduction (29%); use of erythropoietin (54%); required blood transfusion (12%)